biologic

Imaavy

nipocalimab-aahu

Loss of exclusivityApril 2037projected — 12-year biologic exclusivity estimate
CompanyJanssen BiotechView the full company profile on CliffBio

Drug detail

Brand nameImaavy
Active ingredientnipocalimab-aahu
Strength300MG/1.62ML (185MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalApril 2025
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Not found